TrialSignal
Clinical trial intelligence report
Imaging of Tumour Microenvironment in Patients With Oropharyngeal Head and Neck Squamous Cell Carcinoma Using RGD PET/CT Imaging
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT04222543-Jul 28, 2026
NCT ID
NCT04222543
Status
UNKNOWN
Phase
PHASE2
Sponsor
Radboud University Medical Center
Executive brief
Investment-Ready Snapshot
Imaging of Tumour Microenvironment in Patients With Oropharyngeal Head and Neck Squamous Cell Carcinoma Using RGD PET/CT Imaging is a PHASE2 clinical asset sponsored by Radboud University Medical Center in Oropharyngeal Squamous Cell Carcinoma. SEO and diligence focus: RGD PET/CT, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT04222543
Indication
Oropharyngeal Squamous Cell Carcinoma
Modality
combination therapy
Target
RGD PET/CT
Intervention
RGD PET/CT
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.